Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa, First-in-human, Open-label, Multi-site, Multi-regional, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors

NCT07455734 is registered in ClinicalTrials.gov with BioNTech SE as lead sponsor.

NCT NCT07455734
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07455734 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa, First-in-human, Open-label, Multi-site, Multi-regional, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors
Lead sponsor
BioNTech SE
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 30, 2026
Completion date
October 31, 2030
Enrollment
533 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor cancer